Is Sensei Biotherapeutics, Inc. (SNSE) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 10.2% / 30% | 109.2% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 10.2% / 33% | 109.2% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 8.5% / 33% | 91.1% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 10.2% / 33% | 109.2% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 8.5% / 33% | 91.1% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -70.2% | |
| Return on Assets (ROA) | -37.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$25M |
| Free Cash Flow | -$25M |
| Total Debt | $4M |
| Debt-to-Equity | 8.8 |
| Current Ratio | 5.8 |
| Total Assets | $45M |
Price & Trading
| Last Close | $26.88 |
| 50-Day MA | $21.26 |
| 200-Day MA | $12.05 |
| Avg Volume | 327K |
| Beta | -0.1 |
|
52-Week Range
$5.00
| |
About Sensei Biotherapeutics, Inc. (SNSE)
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its solnerstotug program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Sensei Biotherapeutics, Inc. (SNSE) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Sensei Biotherapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Sensei Biotherapeutics, Inc.'s debt ratio?
Sensei Biotherapeutics, Inc.'s debt ratio is 10.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 8.5%.
What are Sensei Biotherapeutics, Inc.'s key financial metrics?
Sensei Biotherapeutics, Inc. has a market capitalization of $35M. Return on equity stands at -70.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.